MusclePharm Corporation (MSLP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MusclePharm Corporation (MSLP) trades at $0.0002 with AI Score 38/100 (Grade D). MusclePharm Corporation, established in 2006, develops, manufactures, and distributes dietary supplements and sports nutrition products under brands like MusclePharm and FitMiss. Sector: Consumer defensive.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MSLP: MSLP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MSLP against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MSLP: 2/3 scored disciplines lean bearish. Dominant signal: Moon AI bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MusclePharm Corporation (MSLP) Consumer Business Overview
MusclePharm Corporation is a Las Vegas-based developer and global distributor of sports nutrition and dietary supplements, including protein powders, bars, and energy drinks under its MusclePharm and FitMiss brands. The company, founded in 2006, is currently navigating Chapter 11 reorganization proceedings, reflecting significant operational and financial complexities within the competitive consumer defensive sector.
What Is the Investment Thesis for MSLP?
MusclePharm Corporation operates within the competitive sports nutrition market, leveraging established brand recognition through its MusclePharm and FitMiss labels and a diverse product portfolio spanning protein powders, bars, and functional energy drinks. Despite these foundational assets, the company is currently navigating significant financial distress, evidenced by its initiation of voluntary Chapter 11 reorganization proceedings on December 15, 2022. The company's reported financials indicate a negative profit margin of -25.7% and a low gross margin of 10.7%, highlighting ongoing operational challenges. Trading on the OTC Other tier with a share price of $0.00 further underscores its precarious financial position and limited market transparency. A potential investment thesis would hinge on the successful outcome of its Chapter 11 restructuring, enabling the company to emerge with a viable business model, improved financial health, and the capacity to capitalize on the growing global sports nutrition market. However, the inherent risks associated with bankruptcy proceedings, intense competition, and the illiquid nature of OTC Other securities demand rigorous due diligence.
Based on FMP financials and quantitative analysis
MSLP Key Highlights
Initiated voluntary Chapter 11 reorganization proceedings with the U.S. Bankruptcy Court for the District of Nevada on December 15, 2022.
- Operates with a negative profit margin of -25.7%, indicating significant financial challenges.
- Maintains a gross margin of 10.7%, reflecting pressure on its cost of goods sold relative to revenue.
- Trades on the OTC Other tier, signifying limited public disclosure and heightened investment risk.
- Possesses established brand recognition within the sports nutrition market through its MusclePharm and FitMiss product lines.
Who Are MSLP's Competitors?
MSLP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MKC McCormick & Company, Incorporated | $55.22 | -2.23% | $14.9B | 62 |
| HRL Hormel Foods Corporation | $24.42 | +0.35% | $13.4B | 56 |
| DAR Darling Ingredients Inc. | $68.77 | +2.73% | $10.9B | 72 |
| ORKLY Orkla ASA | $11.05 | +1.19% | $10.8B | 53 |
| ORKLF Orkla ASA | $10.90 | +0.00% | $10.7B | 56 |
| PPC Pilgrim's Pride Corporation | $31.28 | +9.79% | $7.44B | 58 |
| LW Lamb Weston Holdings, Inc. | $53.86 | +3.62% | $7.40B | 62 |
| CPB Campbell Soup Company | $23.81 | +4.16% | $7.10B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MSLP's Key Strengths?
Established brand recognition with MusclePharm and FitMiss labels.
- Diverse product portfolio covering powders, bars, and energy drinks.
- Global distribution capabilities for its sports nutrition products.
- Focus on specific consumer segments, such as female fitness enthusiasts.
What Are MSLP's Weaknesses?
Ongoing Chapter 11 reorganization proceedings since December 2022.
- Negative profit margin of -25.7% and low gross margin of 10.7%.
- Low share price of $0.00 and OTC Other listing indicating significant financial challenges.
- Limited public disclosure and transparency due to OTC Other tier status.
What Could Drive MSLP Stock Higher?
MSLP catalyst: Chapter 11 Reorganization Proceedings: The company initiated voluntary Chapter 11 reorganization on December 15, 2022.
- The ongoing legal process to restructure its debt and operations is a critical determinant of its future viability and market position, with key milestones in the proceedings serving as potential catalysts.
- Successful Emergence from Chapter 11: A successful resolution of the Chapter 11 proceedings, leading to the company's emergence from bankruptcy with a viable business plan and restructured balance sheet, would be a significant positive catalyst, potentially restoring investor confidence and operational stability.
- Product Innovation and Market Re-entry: Post-reorganization, the introduction of new or reformulated products under its established brands, coupled with a renewed marketing and distribution strategy, could signal a revitalized operational focus and potential for regaining market share in the sports nutrition sector.
What Are the Key Risks for MSLP?
Chapter 11 Reorganization Outcome: The ongoing Chapter 11 proceedings carry the significant risk of an unfavorable outcome, including potential liquidation, severe dilution of existing shareholders, or a restructuring plan that fails to establish long-term viability.
- Negative Financial Performance: The company currently operates with a negative profit margin of -25.7% and a low gross margin of 10.7%, indicating persistent financial challenges that could hinder any recovery efforts and make it difficult to attract new capital or achieve profitability.
- Intense Market Competition: The sports nutrition and dietary supplement market is highly competitive, with numerous established players and new entrants. MusclePharm faces an uphill battle to regain market share and profitability against well-capitalized and innovative competitors.
- Regulatory Scrutiny and Compliance: The dietary supplement industry is subject to evolving regulatory oversight from agencies like the FDA. Any non-compliance, adverse regulatory actions, or changes in regulations could negatively impact product sales, brand reputation, and operational costs.
- Liquidity and Trading Challenges: As an OTC Other listed stock with a low share price, the company faces inherent risks related to extremely low liquidity, wide bid-ask spreads, and difficulty in attracting investor interest, potentially limiting its ability to raise capital or provide shareholder exit opportunities.
What Are the Growth Opportunities for MSLP?
- Expanding within the Global Sports Nutrition Market: The sports nutrition market continues to exhibit robust growth, driven by increasing health consciousness, active lifestyles, and the professionalization of sports. This market includes protein products, pre-workouts, and recovery supplements. MusclePharm, with its established MusclePharm and Combat brands, could potentially capitalize on this trend by re-establishing its market presence and innovating within these core categories post-reorganization. The global sports nutrition market was valued at approximately $45 billion in 2022 and is projected to grow at a CAGR of 8-10% over the next five years, offering a substantial addressable market for a revitalized entity.
- Targeting the Growing Female Fitness Segment: The FitMiss product line specifically caters to female consumers, addressing needs like weight management, lean muscle development, and overall wellness. This segment of the sports nutrition market is experiencing accelerated growth as more women engage in fitness activities and seek tailored nutritional support. By enhancing and expanding the FitMiss brand, MusclePharm could tap into this underserved yet rapidly expanding demographic. The female sports nutrition market is a significant sub-segment, with increasing demand for products designed with specific physiological and lifestyle considerations in mind, presenting a distinct growth vector.
- Capitalizing on the Functional Energy Drink Market: MusclePharm's Combat Energy and FitMiss Energy brands position it within the functional energy drink sector, which is distinct from traditional carbonated soft drinks. This market is driven by consumer demand for beverages offering benefits beyond basic hydration, such as enhanced focus, sustained energy, and nutritional value. With strategic product development and distribution, particularly post-reorganization, MusclePharm could leverage its existing brand equity to expand its footprint in this dynamic category. The global functional beverage market, including energy drinks, is projected to reach over $200 billion by 2028, indicating substantial room for growth.
- Leveraging E-commerce and Direct-to-Consumer (DTC) Channels: The shift towards online retail and DTC models provides significant opportunities for supplement companies to reach a broader audience, control brand messaging, and improve profit margins by reducing reliance on traditional retail intermediaries. For MusclePharm, a renewed focus on optimizing its e-commerce platform and digital marketing strategies could facilitate direct engagement with consumers, gather valuable data, and efficiently launch new products. This approach allows for greater agility in responding to market trends and building a loyal customer base, crucial for a company aiming for a strong comeback.
- Innovation in Product Formulations and Delivery Systems: The sports nutrition market is constantly evolving with new scientific research and consumer preferences for novel ingredients and convenient formats. Opportunities exist in developing plant-based proteins, clean label products, personalized nutrition solutions, and alternative delivery systems like gummies or ready-to-drink shakes. MusclePharm, with its history of product development, could re-invest in R&D to introduce cutting-edge formulations that address specific performance goals or dietary requirements, thereby differentiating its offerings and attracting new customer segments in a competitive landscape.
What Are MSLP's Competitive Advantages?
- Established brand recognition within the sports nutrition market through its MusclePharm and FitMiss labels.
- Diverse product portfolio catering to various fitness goals, dietary needs, and consumer segments.
- Global distribution capabilities for its range of dietary supplements and nutritional goods.
- Proprietary formulations and product development expertise in the competitive supplement industry.
What Does MSLP Do?
MusclePharm Corporation, established in 2006 and headquartered in Las Vegas, Nevada, has built its business around the crafting, production, promotion, and global distribution of dietary supplements and sports-related nutritional goods. The company's extensive product line is meticulously designed to cater to athletes and fitness enthusiasts across various stages of their wellness journeys. Its offerings come in diverse formats, including performance-boosting powders, encapsulated supplements, tablets, gels, and convenient, ready-to-consume snack items such as protein bars. The flagship MusclePharm label encompasses key products like Combat protein powder and Combat Crunch protein bars, alongside essential supplements such as BCAAs, creatine, glutamine, carnitine, CLA, fish oil, and comprehensive multi-vitamins, all aimed at enhancing athletic performance and recovery. Further diversifying its market reach, MusclePharm also markets the FitMiss range of sports nutrition, which is specifically formulated for female consumers. This line supports goals related to weight control, developing lean muscle mass, improving body composition, and overall well-being, acknowledging the distinct nutritional needs of women. In addition to supplements, MusclePharm produces functional energy drinks, sold under the Combat Energy and FitMiss Energy brands, tapping into the growing demand for performance-enhancing beverages. A pivotal event in the company's recent history occurred on December 15, 2022, when MusclePharm Corporation initiated voluntary Chapter 11 reorganization proceedings with the U.S. Bankruptcy Court for the District of Nevada, marking a significant phase in its operational and financial evolution.
What Products and Services Does MSLP Offer?
- Crafts and produces a wide range of dietary supplements.
- Manufactures and distributes sports-related nutritional goods globally.
- Offers performance-boosting powders, encapsulated supplements, tablets, and gels.
- Provides convenient, ready-to-consume snack items, notably Combat Crunch protein bars.
- Markets products under its flagship MusclePharm label, including Combat protein powder.
- Sells the FitMiss range of sports nutrition specifically formulated for female consumers.
- Produces functional energy drinks under the Combat Energy and FitMiss Energy brands.
How Does MSLP Make Money?
- Develops proprietary formulations for its portfolio of sports nutrition and dietary supplements.
- Manufactures products, potentially utilizing both in-house capabilities and third-party contract manufacturers.
- Distributes its branded products globally through various sales channels, including retail and potentially direct-to-consumer.
- Generates revenue primarily from the sale of its MusclePharm, FitMiss, Combat Energy, and FitMiss Energy branded products.
What Industry Does MSLP Operate In?
MusclePharm Corporation operates within the Consumer Defensive sector, specifically the Packaged Foods industry, with a core focus on the sports nutrition and dietary supplements segment. This market is characterized by robust growth, driven by increasing global health consciousness, rising participation in fitness activities, and a growing demand for performance-enhancing and wellness-focused products. The competitive landscape is highly fragmented, featuring a mix of large multinational consumer goods companies, specialized supplement manufacturers, and emerging direct-to-consumer brands. MusclePharm, with its MusclePharm and FitMiss brands, has historically carved out a niche, but its current Chapter 11 status places it in a challenging position relative to more financially stable competitors. The industry is also subject to evolving consumer preferences for 'clean label' products, plant-based options, and functional benefits, necessitating continuous innovation and adaptation.
Who Are MSLP's Key Customers?
- Athletes seeking to enhance performance, aid recovery, and build muscle mass.
- Fitness enthusiasts focused on achieving specific body composition and wellness goals.
- Individuals pursuing weight management and overall health improvements.
- Female consumers targeted by the FitMiss brand for tailored sports nutrition solutions.
- Consumers seeking functional energy drinks for sustained energy and mental focus.
Company Profile
MusclePharm Corporation operates in the Packaged Foods industry within the Consumer Defensive sector. It is headquartered in Burbank, US. The company is led by CEO Ryan Charles Drexler. MSLP has traded publicly since 2010.
MusclePharm Corporation (MSLP) Valuation Context
Relative to its peer group, MSLP's quantitative score of 38/100 is below the peer average of 60/100.
Key Financial Metrics
Return on equity for MusclePharm Corporation stands at 45.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching.
MSLP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Insiders seem to be positioning for something positive, recent activity suggests confidence from within.
- There's a notable buzz in the community about potential new partnerships or product lines.
- The overall market perception seems to be shifting, with more mentions focusing on long-term value.
- Despite some headwinds, the community's long-term holders appear to be doubling down on their convictions.
Bear Case
- The community is getting jittery about the company's ability to navigate current market conditions.
- There's a growing concern that the company might be facing challenges in adapting to changing consumer preferences.
- Recent chatter suggests some major players are reducing their exposure, which could signal caution.
- The overall sentiment seems to be leaning towards a 'wait and see' approach, indicating a lack of immediate conviction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MSLP Latest News
No recent news available for MSLP.
MSLP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MSLP.
Price Targets
Wall Street price target analysis for MSLP.
MSLP MoonshotScore
What does this score mean?
The MoonshotScore rates MSLP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ryan Charles Drexler
CEO
Unknown. Specific details regarding Ryan Charles Drexler's career history, educational background, and previous roles are not provided in the source data. He is noted as managing 21 employees.
Track Record: Unknown. Key achievements, strategic decisions, or company milestones directly attributable to Ryan Charles Drexler's leadership are not detailed in the provided information.
MSLP OTC Market Information
MusclePharm Corporation trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Companies on this tier typically do not meet the minimum disclosure requirements for higher tiers like OTCQB or OTCQX, and may not file financial reports with the SEC or other regulators. This lack of public information often results in limited transparency, making it challenging for investors to conduct thorough due diligence. The OTC Other tier is often associated with 'dark' or 'default' companies, signifying a higher risk profile compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited or unknown public disclosure, making it difficult to assess the company's true financial health and operational status.
- Extremely low liquidity, leading to wide bid-ask spreads and significant challenges in executing trades.
- High volatility and increased susceptibility to market manipulation due to thin trading and lack of robust oversight.
- Potential for delisting or cessation of trading if the company fails to meet even minimal disclosure requirements or its financial distress worsens.
- Lack of institutional investor interest and analyst coverage, resulting in less efficient pricing and market discovery.
- Verify the current status and details of the Chapter 11 reorganization proceedings with the U.S. Bankruptcy Court.
- Research any available public disclosures, however limited, on the OTC Markets Group website or through legal filings.
- Assess the company's most recent financial statements and operational updates to understand its current viability.
- Investigate any news or press releases regarding management changes, strategic shifts, or product developments.
- Examine historical trading volumes and bid-ask spreads to gauge the actual liquidity of the stock.
- Evaluate the competitive landscape and MusclePharm's potential market position post-reorganization.
- Understand the inherent risks associated with investing in companies on the OTC Other tier, including potential for total loss.
- Established brand names like MusclePharm and FitMiss with recognized products in the sports nutrition market.
- A defined business model focused on manufacturing and distributing dietary supplements and functional beverages.
- History of operations since its establishment in 2006, indicating a past market presence and product development.
- Initiation of formal Chapter 11 reorganization proceedings, a structured legal process for financial restructuring.
- Identified CEO and employee count, suggesting an active, albeit challenged, operational structure.
Common Questions About MSLP (Consumer Defensive)
What does the AI Score mean for MSLP?
MSLP holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. MusclePharm Corporation, established in 2006, develops, manufactures, and distributes dietary supplements and sports nutrition products under brands like MusclePharm and FitMiss. The company …
What does MusclePharm Corporation do?
MusclePharm Corporation is a developer, manufacturer, and global distributor of dietary supplements and sports nutrition products. Its extensive portfolio includes performance-boosting powders, protein bars like Combat Crunch, encapsulated supplements, and functional energy drinks. The company operates under key brands such as MusclePharm, Combat, and FitMiss, the latter specifically targeting female consumers with products for weight management and lean muscle development.
What are the main risks for MSLP?
MusclePharm Corporation faces several significant risks, primarily stemming from its ongoing Chapter 11 reorganization proceedings initiated in December 2022, which could result in an unfavorable outcome or liquidation. Financially, the company exhibits a negative profit margin of -25.7% and a low gross margin of 10.7%, indicating deep operational challenges.
How does MusclePharm Corporation adapt to changing consumer preferences in the sports nutrition market?
Historically, MusclePharm Corporation has demonstrated adaptation through its diverse product portfolio and targeted branding. The company offers a wide array of products, from traditional protein powders and creatine to convenient protein bars and functional energy drinks, catering to varied consumer needs and preferences for different formats.
What is MSLP's dividend and shareholder return track record?
MusclePharm Corporation currently has no dividend yield, as the company does not pay dividends to its shareholders. Given its ongoing Chapter 11 reorganization proceedings and significant financial challenges, including a negative profit margin, the company's focus is on restructuring and achieving financial stability rather than returning capital to shareholders through dividends.
What are the key factors to evaluate for MSLP?
MusclePharm Corporation (MSLP) holds an AI score of 38/100 (low). MusclePharm Corporation operates within the competitive sports nutrition market, leveraging established brand recognition through its MusclePharm and FitMiss labels and a diverse product portfolio spanning protein powders, bars, and functional energy drinks. Not financial advice.
How frequently does MSLP data refresh on this page?
MSLP's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MSLP's recent stock price performance?
MusclePharm Corporation (MSLP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition with MusclePharm and FitMiss labels. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MSLP overvalued or undervalued right now?
MusclePharm Corporation (MSLP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details are not available in the provided source data.
- Competitor tickers were not provided in the source data.
- Disclosure status for OTC is unknown as per source data.